Title: | Early response and safety of lenvatinib for patients with advanced hepatocellular carcinoma in a real-world setting |
Authors: | Sho, Takuya Browse this author |
Suda, Goki Browse this author →KAKEN DB |
Ogawa, Koji Browse this author →KAKEN DB |
Kimura, Megumi Browse this author |
Shimazaki, Tomoe Browse this author |
Maehara, Osamu Browse this author |
Shigesawa, Taku Browse this author |
Suzuki, Kazuharu Browse this author |
Nakamura, Akihisa Browse this author |
Ohara, Masatsugu Browse this author |
Umemura, Machiko Browse this author |
Kawagishi, Naoki Browse this author →KAKEN DB |
Natsuizaka, Mitsuteru Browse this author →KAKEN DB |
Nakai, Masato Browse this author |
Morikawa, Kenichi Browse this author |
Furuya, Ken Browse this author |
Baba, Masaru Browse this author |
Yamamoto, Yoshiya Browse this author |
Kobayashi, Tomoe Browse this author |
Meguro, Takashi Browse this author |
Saga, Akiyoshi Browse this author |
Miyagishima, Takuto Browse this author |
Yokoo, Hideki Browse this author →KAKEN DB |
Kamiyama, Toshiya Browse this author →KAKEN DB |
Taketomi, Akinobu Browse this author →KAKEN DB |
Sakamoto, Naoya Browse this author →KAKEN DB |
Keywords: | early response |
lenvatinib |
real world |
REFLECT |
Issue Date: | Feb-2020 |
Publisher: | John Wiley & Sons |
Journal Title: | JGH open |
Volume: | 4 |
Issue: | 1 |
Start Page: | 54 |
End Page: | 60 |
Publisher DOI: | 10.1002/jgh3.12209 |
Abstract: | Background and AimLenvatinib has been recently approved as a first-line systematic therapy for patients with advanced hepatocellular carcinoma (HCC) based on the results of the phase 3 clinical trial REFLECT. This trial excluded patients with a history of systemic chemotherapy, bile duct invasion, and Child-Pugh grade B. We aimed to investigate the efficacy and safety of lenvatinib for these patients and in the real-world setting. MethodsAmong patients who were administered lenvatinib for advanced HCC between April and October 2018 in Hokkaido University Hospital and related hospitals, we evaluated those who were followed for more than 2 months and whose treatment response was evaluated via dynamic computed tomography at baseline and 2 months after treatment initiation. Meanwhile, patients were excluded if they had decompensated liver cirrhosis, were followed up less than 2 months, or were not evaluated at 2 months. Patients were also stratified according to compliance with the REFLECT inclusion criteria for further analysis. ResultsA total of 41 patients were included; more than 50% did not meet the REFLECT inclusion criteria. In total, 5 (12.2%), 20 (48.8%), 12 (29.3%), and 4 (9.3%) showed complete response, partial response, stable disease, and progressive disease, respectively. The objective response rate was 61.2%. The objective response rate and disease control rate were similar between patients who did and did not meet the REFLECT inclusion criteria. Moreover, the safety profile was also similar between the two patient groups. ConclusionLenvatinib showed high early response rate and tolerability in patients with advanced HCC. Favorable outcomes were similarly observed in patients who did not meet the REFLECT inclusion criteria. |
Rights: | https://creativecommons.org/licenses/by/4.0/ |
Type: | article |
URI: | http://hdl.handle.net/2115/77028 |
Appears in Collections: | 医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|